Skip Navigation
Partner with Us

Clinical Genomic and Translational Data Collaboration

What we do:

  • Black Diamond targets undrugged mutations in patients with genetically defined cancers for whom limited treatment options currently exist. Black Diamond is built upon a deep understanding of cancer genetics, protein structure and function, and drug discovery expertise.
  • The MAP Discovery Engine combines our AI prediction platform with an experimental toolbox of biological and biophysical assays and simulations to de-orphan mutations, understand their oncogenicity, and target them with a MasterKey therapy.

What we want:

We seek collaboration opportunities to broaden the impact of the MAP Discovery Engine by incorporating clinical genomics data early in the drug discovery process

  • To understand cancer- and tumor-specific context of actionable mutations
  • To apply real world evidence to enhance the power of AI-driven oncogenicity prediction
  • To inform translational and clinical strategies by leveraging clinico-genomic real-world data
  • To drive therapeutic biomarker discovery that can be used for patient stratification

What do we offer:

  • Computational identification of driver mutations and characterization of their structural impact, validated in cell and animal models
  • Intelligent drug design via integration of MAP discovery engine prediction and MasterKey design principles
  • An array of in vitro model and in vivo and systems to evaluate potential mutation/inhibitor pairs as novel therapies for high impact human cancers

In-licensing / Out-licensing

What we do:

Black Diamond Therapeutics places a high value on partnering with companies and organizations whose strengths complement our own. Black Diamond is committed to partnering with innovators in the fight against cancer by providing transformational precision therapies to patients worldwide.

Our focus is on:

  • Seeking global and regional partners for discovery, development, and commercialization of MasterKey therapeutics
  • In-licensing opportunities at all development stages with a focus on innovative assets that target key oncogenic signaling pathways
  • Clinical and research collaborations (including combinations) that broaden the potential of our internal programs
Read more about our programs and scientific literature.